Table 2. Relative β-Galactosidase Activity Antiestrogenic YES Assay.

code	antiestrogenic activity fold ± S.D.aThe	code	antiestrogenic activity fold ± S.D.aThe
1A	1.15 ± 0.07	4C	1.09 ± 0.20
1B	1.00 ± 0.03	4D	1.11 ± 0.30
1C	1.15 ± 0.04	4E	0.95 ± 0.11
1D	1.12 ± 0.23	4F	1.28 ± 0.22
1E	1.10 ± 0.16	5A	0.75 ± 0.13
1F	1.19 ± 0.07	5B	1.14 ± 0.01
2A	1.93 ± 0.23	5C	1.05 ± 0.10
2B	1.38 ± 0.12	5D	1.05 ± 0.06
2C	1.06 ± 0.06	5E	1.10 ± 0.12
2D	0.63 ± 0.09	5F	1.07 ± 0.16
2E	1.19 ± 0.06	5G	1.05 ± 0.16
2F	2.32 ± 0.28	6B	0.66 ± 0.37
3B	1.71 ± 0.11	6D	0.62 ± 0.30
3D	1.38 ± 0.15	6E	0.66 ± 0.36
3E	1.53 ± 0.28	6F	0.87 ± 0.12
3F	2.27 ± 0.26	6G	0.62 ± 0.35
3G	2.01 ± 0.23	TAM	0.30 ± 0.08
4A	0.98 ± 0.33	4-OH-TAM	0.21 ± 0.00
4B	0.72 ± 0.21	VIb	0.18 ± 0.06

^aTheantiestrogenic activity is compared to 0.5 nM E2 or 1 nM E2 (set as 1); compounds were screened at a dose of 1 μM in the presence of 0.5 nM E2. All compounds were tested in technical quadruplicates and biological triplicates.

^bPreviously reported compound.²³